A Minnesota jury awarded a woman more than $65 million on Friday after she claimed that lifetime use of Johnson and Johnson baby powder contributed to her cancer. The woman claimed the talcum product exposed her to asbast and that contributed to her developing a lung cancer caused primarily by exposure to the carcinogen. Johnson and Johnson for its part says the powder does not contain asbestous that it will appeal the ruling.The product was taken off shelves in 2020. ...

The announcement is scheduled for 1 p.m. ET at the White House. AbbVie, Bristol Myers Squibb, Gilead Sciences, and Merck are among major drugmakers expected to announce deals to cut ‌prices on some ‌medicines, according to sources familiar with the matter. Swiss drugmakers In July, Trump sent letters to leaders of 17 major pharmaceutical companies, outlining how they should provide so-called most-favored-nation prices to the U.S. government's Medicaid health program for low-income people, and guarantee th ...

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers seven portfolios designed for income investors, including retirees, featuring three buy-and-hold portfolios, three rotational portfolios, and a conservative NPP strategy portfolio [1] - The portfolios aim to create stable, long-term passive income with sustainable yields, including two high-income portfolios and two dividend growth investment (DGI) portfolios [1] Group 2 - The "Financially Free Investor" focuses on investing in dividend-growing stocks with a long-term horizon and employs a unique 3-basket investment approach [2] - This approach aims for 30% lower drawdowns, 6% current income, and market-beating growth over the long term [2] - The service includes a total of 10 model portfolios with varying income targets, buy and sell alerts, and live chat for portfolio management and asset allocation [2]

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Core Insights - President Trump announced a set of drug-pricing agreements with nine major pharmaceutical companies, aiming to align U.S. medicine costs with those in Europe [1][2] - The initiative includes a new direct-to-consumer portal, TrumpRx.gov, allowing patients to purchase certain medicines directly from manufacturers [2][4] Group 1: Agreements and Participants - The agreements involve 14 out of 17 drugmakers that Trump previously urged to lower prices, including Amgen, GSK, and Merck [2][3] - Drug companies are motivated to negotiate to avoid potential regulatory measures that could impact their profits [3] Group 2: TrumpRx.gov Functionality - TrumpRx.gov will serve as a central directory for patients to access selected medicines directly from manufacturers' websites [4] - The portal is expected to be fully operational by January, following a promotional launch [4] Group 3: Pricing Details - Highlighted medicines include Amgen's Repatha at $239/month, GSK's Advair Diskus at $89/month, and Merck's Januvia at $100/month [6] - Gilead's Epclusa will be priced at $2,492/month, despite lower costs for insured patients [6] Group 4: Impact on Medicaid and Medicare - Companies committed to launching new medicines in the U.S. at prices comparable to those in other wealthy countries [8] - Medicaid programs are legally entitled to the lowest drug prices, with Bristol Myers Squibb offering Eliquis free to Medicaid [9] Group 5: Industry Response and Future Outlook - Health policy experts express skepticism about the agreements' impact on overall drug prices for most Americans [10] - The agreements do not impose mandatory price controls and leave many brand-name drug costs unchanged [15] - Ongoing discussions with additional manufacturers like AbbVie and Johnson & Johnson may lead to further agreements [14]

Core Points - A Minnesota jury awarded $65.5 million to a plaintiff after finding Johnson & Johnson liable for exposing her to asbestos through its talc products, contributing to her mesothelioma diagnosis [1][2] - The trial revealed that Johnson & Johnson marketed talc-based products despite knowing the risk of asbestos contamination, which is a known carcinogen [2][4] - This verdict is considered the largest asbestos-related verdict in Minnesota's history, covering both economic and non-economic losses [5] Company Accountability - The case emphasized the need for accountability from Johnson & Johnson regarding its marketing practices and the safety of its products [4] - Evidence presented during the trial indicated that the company had knowledge for decades about the potential asbestos contamination in talc deposits but continued to promote its products as safe [4] Legal Context - The plaintiff, Anna Jean Houghton Carley, was diagnosed with mesothelioma in 2025, attributed to her exposure to Johnson & Johnson's baby powder during childhood [3] - The trial team included attorneys from Dean Omar Branham Shirley and Sieben Polk, P.A., who have previously secured significant verdicts against Johnson & Johnson related to talc products [5][6]

Group 1 - Johnson & Johnson (NYSE: JNJ) has shown a 10% upside recently, attributed to a rotation of investment from high-flying tech stocks like Meta, Microsoft, and NVIDIA to more stable growth areas such as healthcare [1] - The company develops and sells a wide range of healthcare products, including pharmaceuticals and medical technologies, with a focus on immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2] - Johnson & Johnson also provides surgical systems, orthopedic solutions, cardiovascular devices, and vision care products, indicating a diverse product portfolio in the healthcare sector [2] Group 2 - While Johnson & Johnson is recognized for its potential as an investment, certain AI stocks are suggested to offer greater upside potential and lower downside risk, indicating a competitive investment landscape [3]

Core Insights - Donald Trump and nine major pharmaceutical companies have reached agreements to significantly reduce drug prices for the Medicaid program and cash payers, aiming to align US costs with those in other wealthy nations [1][2] Group 1: Price Reductions and Agreements - Drugmakers will cut prices on most drugs sold to Medicaid, promising "massive savings" on commonly used medicines, although specific figures were not disclosed [2] - The deals include agreements to lower cash-pay prices for select drugs, launch drugs in the US at prices equal to those in other wealthy nations, and increase manufacturing [3] - Merck plans to sell its diabetes drugs at approximately 70% off list prices directly to US consumers, with potential for its experimental cholesterol drug to be offered through direct channels [4] Group 2: Previous and Current Deals - Five companies had previously made agreements with the administration to control prices, while three companies have yet to announce deals [6] - Drugmakers committed to "most-favored-nation" pricing for all new US drug launches across various markets, including Medicare [7] Group 3: Financial Commitments and Investments - Companies pledged to invest over $150 billion in US research and development and manufacturing, with Merck contributing $70 billion of that total [8] - A portion of revenues from foreign sales will be remitted to the US to help offset costs [8] Group 4: Medicaid and Market Impact - Medicaid, which represents about 10% of US drug spending, already benefits from significant price discounts, sometimes exceeding 80% [9] - Pfizer indicated that Medicaid discounts would lead to price and margin compression in the upcoming year [9]

Core Points - US President Donald Trump announced agreements with nine major pharmaceutical companies to reduce drug prices for Medicaid and cash-paying consumers, aiming to align US drug costs with those in other wealthy nations [1][4] - Trump emphasized that the US was previously subsidizing global drug costs and will no longer do so [2] Group 1: Drugmakers Involved - Participating companies include Bristol Myers Squibb, Gilead Sciences, Novartis, Amgen, Boehringer Ingelheim, Sanofi, GSK, Merck, and Roche's US unit Genentech [3] - Additional companies like Regeneron, Johnson & Johnson, and AbbVie are expected to join after the holidays [3] Group 2: Price Reductions and Commitments - Drugmakers will reduce prices on most medicines sold to Medicaid, promising "massive savings" on widely used drugs, although specific figures were not disclosed [4] - The agreements also include commitments to cut cash prices for select medicines and to launch new drugs in the US at prices equal to those in other wealthy countries [5] Group 3: Specific Drug Pricing - Merck plans to sell diabetes drugs Januvia, Janumet, and Janumet XR at discounts of about 70% off list prices [7] - Amgen will price its migraine drug Aimovig and arthritis treatment Amjevita at $299 per month, which is nearly 60% and 80% below current US list prices, respectively [7] Group 4: Investment and Revenue Sharing - Companies pledged to invest over $150 billion in US research, development, and manufacturing, with Merck alone committing $70 billion [8] - A portion of each company's overseas revenue will be remitted to the US to help offset domestic drug costs, and several companies agreed to donate drug ingredients to the US strategic reserve [9] Group 5: Industry Reaction - Five drugmakers, including Pfizer and Eli Lilly, had already struck similar deals with the administration, and AbbVie is expected to announce its agreement soon [10]

责任编辑：张俊 SF065 强生公司（JNJ）周五早盘上涨0.4%，该公司获得美国食品与药物管理局（FDA）批准：其 RYBREVANT FASPRO（amivantamab与透明质酸酶组合）可与lazertinib联用，用于一线治疗EGFR突变 非小细胞肺癌，实现5分钟皮下注射给药。 责任编辑：张俊 SF065 强生公司（JNJ）周五早盘上涨0.4%，该公司获得美国食品与药物管理局（FDA）批准：其 RYBREVANT FASPRO（amivantamab与透明质酸酶组合）可与lazertinib联用，用于一线治疗EGFR突变 非小细胞肺癌，实现5分钟皮下注射给药。 ...